VIDA FLaSH Acquisitions in an amended S-1 filing said it plans to offer 15 million units at $10 each in its IPO — down nearly 14 percent from the 17.5 million units planned in the SPAC’s initial registration last month.
The new SPAC plans to target the healthcare sector in the United States.
VIDA is led by CEO and Director Dr. Frank Litvack, an interventional cardiologist and former co-director of the Cardiovascular Intervention Center at Cedars Sinai in Los Angeles and a Professor of Medicine at UCLA.
The SPAC intends to list on the Nasdaq under FLSHU. Read more.
